Evidence map›Paper›PMID 19322630›Full record

ArticleInternational journal of hematology2009

t(5;6;12) associated with resistance to imatinib mesylate in chronic myeloid leukemia.

Marija Denčić-Fekete, Vesna Đorđević, Clelia Tiziana Storlazzi, Gradimir Janković, Andrija Bogdanović, Jelica Jovanović, Mariano Rocchi, Biljana Todorić-Živanović, Milica Strnad, Mirjana Gotić

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Marija Denčić-FeketeClinical Center Serbia, Institute of Hematology, Koste Todorovića 2 Street, 11000, Belgrade, Serbia. mdencicfekete@yahoo.com.
Vesna ĐorđevićClinical Center Serbia, Institute of Hematology, Koste Todorovića 2 Street, 11000, Belgrade, Serbia.
Clelia Tiziana StorlazziDepartment of Genetics and Microbiology, University of Bari, Bari, Italy.
Gradimir JankovićClinical Center Serbia, Institute of Hematology, Koste Todorovića 2 Street, 11000, Belgrade, Serbia.
Andrija BogdanovićClinical Center Serbia, Institute of Hematology, Koste Todorovića 2 Street, 11000, Belgrade, Serbia.
Jelica JovanovićClinical Center Serbia, Institute of Hematology, Koste Todorovića 2 Street, 11000, Belgrade, Serbia.
Mariano RocchiDepartment of Genetics and Microbiology, University of Bari, Bari, Italy.
Biljana Todorić-ŽivanovićMilitary Medical Academy, 11000, Belgrade, Serbia.
Milica StrnadMilitary Medical Academy, 11000, Belgrade, Serbia.
Mirjana GotićClinical Center Serbia, Institute of Hematology, Koste Todorovića 2 Street, 11000, Belgrade, Serbia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A patient with t(9;22)-positive chronic myelogenous leukemia (CML) developed a resistance to therapy with imatinib mesylate (Glivec) which coincided with the appearance of t(5;6;12) in the same cells with t(9;22) [46,XX,t(5;6;12)(q14?;q21?;q23?),t(9;22)(q34;q11)]. She remains in a continuous chronic phase of CML. This is the first reported instance of karyotype evolution temporally associated, and possibly involved, with the induction of resistance to imatinib mesylate but without any signs of evolution of leukemia toward a more anaplastic and aggressive form.

Indexed as

AdultAntineoplastic AgentsBenzamidesChromosomes, HumanChromosomes, Human, Pair 12Chromosomes, Human, Pair 5Chromosomes, Human, Pair 6Drug Resistance, NeoplasmFemaleHumansImatinib MesylateKaryotypingLeukemia, Myelogenous, Chronic, BCR-ABL PositivePiperazinesPyrimidinesAntineoplastic AgentsBenzamidesImatinib MesylatePiperazinesPyrimidines

Identifiers

PMID19322630

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.